IL10RA and inflammatory bowel disease: In the past years, it has been shown that a group of VEO-IBD patients harbor genetic defects in the interleukin-10 receptor (IL-10R), which abrogate the anti-inflammatory effect of interleukin IL-10 and lead to the development of severe bowel inflammation within the first six years of life [2,5,6,7].